Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C68819
http://purl.obolibrary.org/obo/NCIT_C68819
|
|---|---|
| Preferred Name | Moxetumomab Pasudotox |
| Definitions |
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22. |
|---|---|
| prefLabel | Moxetumomab Pasudotox
|
| label | Moxetumomab Pasudotox
|
| PDQ_Closed_Trial_Search_ID | 540032
|
| code | C68819
|
| prefixIRI | NCIT:C68819
|
| in_subset |
See more
See less
|
| Display_Name | Moxetumomab Pasudotox
|
| Preferred_Name | Moxetumomab Pasudotox
|
| FDA_UNII_Code | 2NDX4B6N8F
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Moxetumomab Pasudotox
|
| CAS_Registry | 1020748-57-5
|
| NCI_Drug_Dictionary_ID | 540032
|
| Legacy Concept Name | Anti-CD22_Immunotoxin_CAT-8015
|
| type | |
| ALT_DEFINITION | A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22 immunotoxin CAT-8015 is made in the laboratory. It binds to CD22, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 540032
|
| Accepted_Therapeutic_Use_For | relapsed or refractory hairy cell leukemia (HCL)
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C2717021
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |